Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Overleving oudere CML-patiënt blijft achter, ook in TKI-tijdperk
jul 2020 | Leukemie, Ouderen